Cited by 1,993Acute Myeloid Leukemia ResearchCancer Genomics and DiagnosticsChromatin Remodeling and Cancer

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

Open access

Ding, Li, Ley, Timothy J., Larson, David E., Miller, Christopher A., Koboldt, Daniel C., Welch, John S., Ritchey, Julie K., Young, Margaret A., Lamprecht, Tamara, McLellan, Michael D., McMichael, Joshua F., Wallis, John W., Lu, Charles, Shen, Dong, Harris, Christopher C., Dooling, David J., Fulton, Robert S., Fulton, Lucinda L., Chen, Ken, Schmidt, Heather, Kalicki-Veizer, Joelle, Magrini, Vincent J., Cook, Lisa, McGrath, Sean D., Vickery, Tammi L., Wendl, Michael C., Heath, Sharon, Watson, Mark A., Link, Daniel C., Tomasson, Michael H., Shannon, William D., Payton, Jacqueline E., Kulkarni, Shashikant, Westervelt, Peter, Walter, Matthew J., Graubert, Timothy A., Mardis, Elaine R., Wilson, Richard K., DiPersio, John F.·2012·Nature

DOI 10.1038/nature10738PMC PMC3267864

Open this paper in CoChat — free account Open PDF

Abstract

The sequencing of AML genomes of eight patients before and after relapse reveals two major patterns of clonal evolution, with chemotherapy appearing to have a role in both patterns. Many patients with acute myeloid leukaemia (AML) achieve remission, but it is often short-lived and the returned disease is usually refractory to therapy. Genome sequencing of eight patients with AML before and after relapse reveals two major patterns of tumour cell evolution. The founding clone survives chemotherapy in all patients, and, in one clonal pattern, it acquires new mutations and expands at relapse. In the other, a subclone surviving from the original tumour expands and then acquires new mutations. Comparisons of relapse-specific and primary tumour mutations point to an increase in transversions, implying DNA damage caused by cytotoxic chemotherapy. This work demonstrates that the AML genome in an individual patient presents a moving target, and highlights the importance of striving to eradicate both the founding clone and all of its subclones. Most patients with acute myeloid leukaemia (AML) die from progressive disease after relapse, which is associated with clonal evolution at the cytogenetic level1,2 . To determine the mutational spectrum associated with relapse, we sequenced the primary tumour and relapse genomes from eight AML patients, and validated hundreds of somatic mutations using deep sequencing; this allowed us to define clonality and clonal evolution patterns precisely at relapse. In addition to discovering novel, recurrently mutated genes (for example, WAC, SMC3, DIS3, DDX41 and DAXX) in AML, we also found two major clonal evolution patterns during AML relapse: (1) the founding clone in the primary tumour gained mutations and evolved into the relapse clone, or (2) a subclone of the founding clone survived initial therapy, gained additional mutations and expanded at relapse. In all cases, chemotherapy failed to eradicate the founding clone. The comparison of relapse-specific versus primary tumour mutations in all eight cases revealed an increase in transversions, probably due to DNA damage caused by cytotoxic chemotherapy. These data demonstrate that AML relapse is associated with the addition of new mutations and clonal evolution, which is shaped, in part, by the chemotherapy that the patients receive to establish and maintain remissions.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature10738

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Self-citation
Tumour evolution inferred by single-cell sequencing
Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., Cook, K., Stepansky, A., Levy, D., Esposito, D., et al. (2011) · Nature · doi:10.1038/nature09807 · Cited by 2,598
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Self-citation
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Self-citation
Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype
Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041974 · Cited by 1,892
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Puente, X. S., Pinyol, M., Quesada, V., Conde, L., Ordóñez, G. R., Villamor, N., Escaramís, G., Jares, P., Beà, S., González, M., et al. (2011) · Nature · doi:10.1038/nature10113 · Cited by 1,529
BreakDancer: an algorithm for high-resolution mapping of genomic structural variation
Chen, K., Wallis, J. W., McLellan, M. D., Larson, D. E., Kalicki, J. M., Pohl, C. S., McGrath, S. D., Wendl, M. C., Zhang, Q., Locke, D. P., et al. (2009) · Nature Methods · doi:10.1038/nmeth.1363 · Cited by 1,489

Show all 30 references

Sorted by citations

Items 501–600 of 999

NanoRNP Overcomes Tumor Heterogeneity in Cancer Treatment
Liu, Q., Cai, J., Zheng, Y., Tan, Y., Wang, Y., Zhang, Z., Zheng, C., Zhao, Y., Liu, C., An, Y., et al. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b02501 · Cited by 67
The evolution of the unstable cancer genome
Burrell, R. A., & Swanton, C. (2014) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.11.011 · Cited by 66
Mutation–selection balance and compensatory mechanisms in tumour evolution
Persi, E., Wolf, Y. I., Horn, D., Ruppin, E., Demichelis, F., Gatenby, R. A., Gillies, R. J., & Koonin, E. V. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-00299-4 · Cited by 64
Gene mutations of acute myeloid leukemia in the genome era
Naoe, T., & Kiyoi, H. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1257-4 · Cited by 68
Biological implications of somatic DDX41 p.R525H mutation in acute myeloid leukemia
Kadono, M., Kanai, A., Nagamachi, A., Shinriki, S., Kawata, J., Iwato, K., Kyo, T., Oshima, K., Yokoyama, A., Kawamura, T., et al. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.04.017 · Cited by 64
Single-cell genomics in AML: extending the frontiers of AML research
Ediriwickrema, A., Gentles, A. J., & Majeti, R. (2022) · Blood · doi:10.1182/blood.2021014670 · Cited by 69
The end of the genetic paradigm of cancer
Huang, S., Soto, A. M., & Sonnenschein, C. (2025) · PLoS Biology · doi:10.1371/journal.pbio.3003052 · Cited by 68
Next‐generation sequencing – feasibility and practicality in haematology
Kohlmann, A., Großmann, V., Nadarajah, N., & Haferlach, T. (2013) · British Journal of Haematology · doi:10.1111/bjh.12194 · Cited by 65
Microfluidics for single-cell genetic analysis
Thompson, A. M., Paguirigan, A. L., Kreutz, J. E., Radich, J. P., & Chiu, D. T. (2014) · Lab on a Chip · doi:10.1039/c4lc00175c · Cited by 65
Resilient and resourceful: Genome maintenance strategies in hematopoietic stem cells
Bakker, S. T., & Passegue, E. A. (2013) · Experimental Hematology · doi:10.1016/j.exphem.2013.09.007 · Cited by 67
Shimmer: detection of genetic alterations in tumors using next-generation sequence data
Hansen, N. F., Gartner, J. J., Mei, L., Samuels, Y., & Mullikin, J. C. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt183 · Cited by 64
Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant
Jacoby, M. A., Duncavage, E. J., Chang, G. S., Miller, C. A., Shao, J., Elliott, K., Robinson, J., Fulton, R. S., Fronick, C. C., O’Laughlin, M. D., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98962 · Cited by 65
Single-Cell Omics Analyses Enabled by Microchip Technologies
Deng, Y., Finck, A., & Fan, R. (2019) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-060418-052538 · Cited by 65
Concise Review: Preleukemic Stem Cells: Molecular Biology and Clinical Implications of the Precursors to Leukemia Stem Cells
Pandolfi, A., Barreyro, L., & Steidl, U. G. (2013) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0109 · Cited by 66
Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia
Sood, R. B., Hansen, N. F., Donovan, F. X., Carrington, B., Bucci, D. M., Maskeri, B., Young, A., Trivedi, N. S., Kohlschmidt, J., Stone, R. M., et al. (2015) · Leukemia · doi:10.1038/leu.2015.141 · Cited by 63
Cohesin gene mutations in tumorigenesis: from discovery to clinical significance
Solomon, D. A., Kim, J.-S., & Waldman, T. A. (2014) · BMB Reports · doi:10.5483/bmbrep.2014.47.6.092 · Cited by 65
Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs
Zebisch, A., Hatzl, S., Pichler, M., Wölfler, A., & Sill, H. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122080 · Cited by 63
Time to repeal and replace response criteria for acute myeloid leukemia?
Bloomfield, C. D., Estey, E. H., Pleyer, L., Schuh, A. C., Stein, E. M., Tallman, M. S., & Wei, A. H. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.03.006 · Cited by 63
Treatment resistance in urothelial carcinoma: an evolutionary perspective
Vlachostergios, P. J., & Faltas, B. M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0026-y · Cited by 62
SubcloneSeeker: a computational framework for reconstructing tumor clone structure for cancer variant interpretation and prioritization
Qiao, Y., Quinlan, A. R., Jazaeri, A. A., Verhaak, R. G. W., Wheeler, D. A., & Marth, G. (2014) · Genome biology · doi:10.1186/preaccept-1691129011290725 · Cited by 61
Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling
WICKI, A. N., Mandalà, M., Massi, D., Taverna, D., Tang, H., Hemmings, B. A., & Xue, G. (2016) · Physiological Reviews · doi:10.1152/physrev.00024.2015 · Cited by 64
Extracellular Vesicles and Chemotherapy Resistance in the AML Microenvironment
Nehrbas, J. F., Butler, J. T., Chen, D.-W., & Kurre, P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00090 · Cited by 62
ASXL1 mutation in clonal hematopoiesis
Fujino, T., & Kitamura, T. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.01.002 · Cited by 64
Genomic characterization of relapsed acute myeloid leukemia reveals novel putative therapeutic targets
Stratmann, S., Yones, S. A., Mayrhofer, M., Norgren, N., Skaftason, A., Sun, J., Smolińska, K., Komorowski, J., Herlin, M. K., Sundström, C., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003709 · Cited by 63
Cancer metabolism and intervention therapy
Zhao, H., & Li, Y. (2021) · Molecular Biomedicine · doi:10.1186/s43556-020-00012-1 · Cited by 67
Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML
Valent, P., Sadovnik, I., Eisenwort, G., Bauer, K., Herrmann, H., Gleixner, K. V., Schulenburg, A., Rabitsch, W., Sperr, W. R., & Wolf, D. G. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174233 · Cited by 60
Implications of intratumour heterogeneity for treatment stratification
Crockford, A., Jamal‐Hanjani, M., Hicks, J. B., & Swanton, C. (2013) · The Journal of Pathology · doi:10.1002/path.4270 · Cited by 59
Polymerase specific error rates and profiles identified by single molecule sequencing
Hestand, M. S., Houdt, J. V., Cristofoli, F., & Vermeesch, J. R. (2016) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2016.01.003 · Cited by 58
Reconciling Non-Genetic Plasticity with Somatic Evolution in Cancer
Huang, S. (2021) · Trends in cancer · doi:10.1016/j.trecan.2020.12.007 · Cited by 60
When clinical heterogeneity exceeds genetic heterogeneity: thinking outside the genomic box in chronic myelomonocytic leukemia
Ball, M., List, A. F., & Padron, E. (2016) · Blood · doi:10.1182/blood-2016-07-692988 · Cited by 63
STING signaling in tumorigenesis and cancer therapy: A friend or foe?
He, L., Xiao, X., Yang, X., Zhang, Z., Wu, L., & Liu, Z. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.05.026 · Cited by 62
Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia
Chen, K. T. J., Gilabert‐Oriol, R., Bally, M. B., & Leung, A. W. Y. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2654-z · Cited by 59
Differential redox-regulation and mitochondrial dynamics in normal and leukemic hematopoietic stem cells: A potential window for leukemia therapy
Mattes, K., Vellenga, E., & Schepers, H. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102814 · Cited by 62
Transcriptional Regulation of Haematopoietic Stem Cells
Wilkinson, A. C., & Göttgens, B. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-6621-1_11 · Cited by 63
Genetic profile of T-cell acute lymphoblastic leukemias with MYC translocations
Starza, R. L., Borga, C., Barba, G., Pierini, V., Schwab, C. J., Matteucci, C., Fernandez, A. G. L., Leszl, A., Cazzaniga, G., Chiaretti, S., et al. (2014) · Blood · doi:10.1182/blood-2014-06-578856 · Cited by 58
The variety of leukemic stem cells in myeloid malignancy
Wiseman, D. H., Greystoke, B., & Somervaille, T. C. P. (2013) · Oncogene · doi:10.1038/onc.2013.269 · Cited by 59
Leukemia-associated activating mutation of Flt3 expands dendritic cells and alters T cell responses
Lau, C. M., Nish, S. A., Yogev, N., Waisman, A., Reiner, S. L., & Reizis, B. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20150642 · Cited by 58
The evolving molecular genetic landscape in acute myeloid leukaemia
Sanders, M. A., & Valk, P. J. M. (2013) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32835d821c · Cited by 59
Accurately Identifying Low-Allelic Fraction Variants in Single Samples with Next-Generation Sequencing: Applications in Tumor Subclone Resolution
Stead, L. F., Sutton, K., Taylor, G. R., Quirke, P., & Rabbitts, P. H. (2013) · Human Mutation · doi:10.1002/humu.22365 · Cited by 57
The rarity of ALDH + cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients
Hoang, V. T., Buss, E. C., Wang, W., Hoffmann, I., Raffel, S., Zepeda‐Moreno, A., Baran, N., Wuchter, P., Eckstein, V., Trumpp, A., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29410 · Cited by 57
Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia
Bibault, J., Figeac, M., Hélevaut, N., Rodriguez, C., Quief, S., Sebda, S., Renneville, A., Nibourel, O., Rousselot, P. H., Gruson, B., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4333 · Cited by 59
Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia
Schlenk, R. F., & Döhner, H. (2013) · Hematology · doi:10.1182/asheducation-2013.1.324 · Cited by 66
Lessons from next-generation sequencing analysis in hematological malignancies
Braggio, E., Egan, J. B., Fonseca, R., & Stewart, A. K. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.26 · Cited by 57
How Do We Use Multicolor Flow Cytometry to Detect Minimal Residual Disease in Acute Myeloid Leukemia?
Xu, J., Jorgensen, J. L., & Wang, S. A. (2017) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2017.07.004 · Cited by 57
Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells
Lee, W.-H. S., Ye, Z., Cheung, A. M. S., Goh, Y., Oh, H. L. J., Rajarethinam, R., Yeo, S. P., Soh, M. K., Chan, E. H. L., Tan, L. K., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0155 · Cited by 57
Regulation of self‐renewal in normal and cancer stem cells
Falzacappa, M. V. V., Ronchini, C., Reavie, L. B., & Pelicci, P. G. (2012) · FEBS Journal · doi:10.1111/j.1742-4658.2012.08727.x · Cited by 61
Next-Generation Sequencing Approaches in Cancer: Where Have They Brought Us and Where Will They Take Us?
Leblanc, V., & Marra, M. A. (2015) · Cancers · doi:10.3390/cancers7030869 · Cited by 57
The population genetics of drug resistance evolution in natural populations of viral, bacterial and eukaryotic pathogens
Wilson, B. A., Garud, N. R., Feder, A. F., Assaf, Z. J. F., & Pennings, P. S. (2015) · Molecular Ecology · doi:10.1111/mec.13474 · Cited by 57
Leaving the Lysosome Behind: Novel Developments in Autophagy Inhibition
Solitro, A. R., & MacKeigan, J. P. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.166 · Cited by 59
DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders
Sato, H., Wheat, J. C., Steidl, U. G., & Ito, K. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00187 · Cited by 59
Acute myeloid leukemia in the vascular niche
Cogle, C. R., Bosse, R. C., Brewer, T. M., Migdady, Y., Shirzad, R., Kampen, K. R., & Saki, N. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.05.007 · Cited by 56
Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma
Chan, F. C., Mottok, A., Gerrie, A. S., Power, M. M., Nijland, M., Diepstra, A., van den Berg, A., Kamper, P., d’Amore, F., d’Amore, A. L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.7925 · Cited by 55
Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma
Robinson, A. M., Rathore, R., Redlich, N. J., Adkins, D. R., VanArsdale, T. L., Tine, B. A. V., & Michel, L. S. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2098-8 · Cited by 56
Inferring structural variant cancer cell fraction
Cmero, M., Yuan, K., Ong, C. S., Schröder, J., PCAWG Evolution and Heterogeneity Working Group, Adams, D. J., Anur, P., Beroukhim, R., Boutros, P. C., Bowtell, D. D. L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14351-8 · Cited by 56
Nanodelivery Systems for Nucleic Acid Therapeutics in Drug Resistant Tumors
Iyer, A. K., Duan, Z., & Amiji, M. M. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500024p · Cited by 55
Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing
Salipante, S. J., Fromm, J. R., Shendure, J., Wood, B. L., & Wu, D. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.57 · Cited by 55
DDX41-related myeloid neoplasia
Maciejewski, J. P., Padgett, R. A., Brown, A. L., & Müller‐Tidow, C. (2017) · Seminars in Hematology · doi:10.1053/j.seminhematol.2017.04.007 · Cited by 55
Multi-region proteome analysis quantifies spatial heterogeneity of prostate tissue biomarkers
Guo, T., Li, L., Zhong, Q., Rupp, N. J., Charmpi, K., Wong, C. E., Wagner, U., Rueschoff, J. H., Jochum, W., Fankhauser, C. D., et al. (2018) · Life Science Alliance · doi:10.26508/lsa.201800042 · Cited by 52
Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial
Stelljes, M., Middeke, J. M., Bug, G., Wagner‐Drouet, E., Müller, L. P., Schmid, C., Krause, S. W., Bethge, W. A., Jost, E., Platzbecker, U., et al. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00065-6 · Cited by 62
Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes
Badar, T., Patel, K. P., Thompson, P. A., Dinardo, C. D., Takahashi, K., Cabrero, M., Borthakur, G. M., Cortes, J. E., Konopleva, M. Y., Kadia, T. M., et al. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.10.005 · Cited by 58
Re-Evaluating Clonal Dominance in Cancer Evolution
Burrell, R. A., & Swanton, C. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.04.002 · Cited by 54
Towards a better understanding of the therapeutic applications and corresponding mechanisms of action of honey
Khan, R. U., Naz, S., & Abudabos, A. M. (2017) · Environmental Science and Pollution Research · doi:10.1007/s11356-017-0567-0 · Cited by 55
Tumor propagating cells: drivers of tumor plasticity, heterogeneity, and recurrence
Vessoni, A. T., Filippi‐Chiela, E. C., Lenz, G., & Batista, L. F. Z. (2019) · Oncogene · doi:10.1038/s41388-019-1128-4 · Cited by 59
CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function
Ruggiero, E., Carnevale, E., Prodeus, A., Magnani, Z. I., Camisa, B., Merelli, I., Politano, C., Stasi, L., Potenza, A., Cianciotti, B. C., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abg8027 · Cited by 58
Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
Vyas, P., Appelbaum, F. R., & Craddock, C. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.10.026 · Cited by 54
Reliable Single Cell Array CGH for Clinical Samples
Czyż, Z. T., Hoffmann, M., Schlimok, G., Polzer, B. M., & Klein, C. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085907 · Cited by 52
Intratumoral Heterogeneity, Its Contribution to Therapy Resistance and Methodological Caveats to Assessment
Renovanz, M., & Kim, E. L. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00142 · Cited by 55
Developmental timing of mutations revealed by whole-genome sequencing of twins with acute lymphoblastic leukemia
Ma, Y. P., Dobbins, S. E., Sherborne, A. L., Chubb, D., Galbiati, M., Cazzaniga, G., Micalizzi, C., Tearle, R. G., Lloyd, A. L., Hain, R. D., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221099110 · Cited by 54
What are we learning from the cancer genome?
Collisson, E. A., Cho, R. J., & Gray, J. W. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.159 · Cited by 55
Next Generation Sequencing of Acute Myeloid Leukemia: Influencing Prognosis
Ilyas, A. M., Ahmad, S., Faheem, M., Naseer, M. I., Kumosani, T., Al-Qahtani, M. H., Gari, M. A., & Ahmed, F. (2015) · BMC Genomics · doi:10.1186/1471-2164-16-s1-s5 · Cited by 55
Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1
Saygin, C., Hirsch, C. M., Przychodzen, B. P., Sekeres, M. A., Hamilton, B. K., Kalaycio, M. E., Carraway, H. E., Gerds, A. T., Mukherjee, S., Nazha, A., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-017-0040-9 · Cited by 51
SuperFreq: Integrated mutation detection and clonal tracking in cancer
Flensburg, C., Sargeant, T., Oshlack, A., & Majewski, I. J. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007603 · Cited by 51
Oxidative stress leads to increased mutation frequency in a murine model of myelodysplastic syndrome
Chung, Y. J., Robert, C., Gough, S. M., Rassool, F. V., & Aplan, P. D. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.07.008 · Cited by 54
Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancer
Hsieh, J. J.-D., Manley, B. J., Khan, N. A., Gao, J., Carlo, M. I., & Cheng, E. H. Y. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.09.002 · Cited by 54
A population genetics perspective on the determinants of intra-tumor heterogeneity
Hu, Z., Sun, R., & Curtis, C. N. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.03.001 · Cited by 54
Targeting the MTF2–MDM2 Axis Sensitizes Refractory Acute Myeloid Leukemia to Chemotherapy
Maganti, H. B., Jrade, H., Cafariello, C., Rothberg, J. L. M., Porter, C. J., Yockell‐Lelièvre, J., Battaion, H. L., Khan, S. T., Howard, J. P., Li, Y., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0841 · Cited by 60
The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?
Arnedos, M., Vielh, P. R., Soria, J., & André, F. (2013) · The Journal of Pathology · doi:10.1002/path.4276 · Cited by 51
Characterization of gene mutations and copy number changes in acute myeloid leukemia using a rapid target enrichment protocol
Bolli, N., Manes, N., McKerrell, T., Chi, J., Park, N., Gundem, G., Quail, M. A., Sathiaseelan, V., Herman, B., Crawley, C. R., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.113381 · Cited by 54
Analytical demands to use whole-genome sequencing in precision oncology
Meggendorfer, M., Jobanputra, V., Wrzeszczyński, K. O., Roepman, P., de Bruijn, E., Cuppen, E. P. J. G., Büttner, R., Caldas, C., Grimmond, S. M., Mullighan, C. G., et al. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.009 · Cited by 51
Exploring the Metabolic Landscape of AML: From Haematopoietic Stem Cells to Myeloblasts and Leukaemic Stem Cells
Mesbahi, Y., Trahair, T. N., Lock, R. B., & Connerty, P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.807266 · Cited by 52
Targeting Glucose Metabolism in Cancer Cells as an Approach to Overcoming Drug Resistance
Cunha, A., Silva, P. M. A., Sarmento, B. F. C. C., & Queirós, O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15112610 · Cited by 59
Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M3P)
Kortüm, K. M., Langer, C., Monge, J., Bruins, L. A., Zhu, Y. X., Shi, C. X., Jedlowski, P. M., Egan, J. B., Ojha, J., Bullinger, L., et al. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2344-9 · Cited by 51
Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia
Gallipoli, P., Giotopoulos, G., & Huntly, B. J. P. (2015) · Therapeutic Advances in Hematology · doi:10.1177/2040620715577614 · Cited by 53
Preleukemic Hematopoietic Stem Cells in Human Acute Myeloid Leukemia
Corces, M. R., Chang, H. Y., & Majeti, R. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00263 · Cited by 56
Complex molecular genetic abnormalities involving three or more genetic mutations are important prognostic factors for acute myeloid leukemia
Wakita, S., Yamaguchi, H., Ueki, T., Usuki, K., Kurosawa, S., Kobayashi, Y., Kawata, E., Tajika, K., Gomi, S., Koizumi, M., et al. (2015) · Leukemia · doi:10.1038/leu.2015.288 · Cited by 52
Systems biology of cancer: entropy, disorder, and selection-driven evolution to independence, invasion and “swarm intelligence”
Tarabichi, M., Antoniou, A., Saiselet, M., Pita, J. M. G., Andry, G., Dumont, J. E., Detours, V., & Maenhaut, C. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9431-y · Cited by 51
Tumor Evolution in Response to Chemotherapy: Phenotype versus Genotype
Navin, N. E. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.01.035 · Cited by 51
Inferring mutational timing and reconstructing tumour evolutionary histories
Turajlic, S., McGranahan, N., & Swanton, C. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.03.005 · Cited by 53
Not Everyone Fits the Mold: Intratumor and Intertumor Heterogeneity and Innovative Cancer Drug Design and Development
Dzobo, K., Senthebane, D. A., Thomford, N. E., Rowe, A., Dandara, C., & Parker, M. I. (2018) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2017.0174 · Cited by 54
Current status and trends in the diagnostics of AML and MDS
Shumilov, E., Flach, J., Kohlmann, A., Banz, Y., Bonadies, N., Fiedler, M., Pabst, T., & Bacher, U. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.04.008 · Cited by 52
The evolutionary history of 2,658 cancersPreprint
Gerstung, M., Jolly, C., Leshchiner, I., Dentro, S. C., González, S., Rosebrock, D., Mitchell, T. J., Rubanova, Y., Anur, P., Yu, K., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/161562 · Cited by 51
Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia
Ling, V., Straube, J., Godfrey, W. A., Haldar, R., Janardhanan, Y., Cooper, L. T., Bruedigam, C., Cooper, E., Shirazi, P. T., Jacquelin, S., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01755-2 · Cited by 49
Unraveling Tumor Grading and Genomic Landscape in Lung Neuroendocrine Tumors
Pelosi, G., Papotti, M. G., Rindi, G., & Scarpa, A. (2014) · Endocrine Pathology · doi:10.1007/s12022-014-9320-0 · Cited by 49
Comparison of Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide: Insight into Mechanisms of Resistance
Chendamarai, E., Ganesan, S., Alex, A. A., Kamath, V., Nair, S. C., Nellickal, A. J., Arthur, N. B. J., Srivastava, V. M., Lakshmi, K. M., Viswabandya, A., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121912 · Cited by 49
Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non–small cell lung cancer negative for EGFR mutation and ALK fusion
Sakai, H., Takeda, M., Sakai, K., Nakamura, Y., Ito, A., Hayashi, H., Tanaka, K., Nishio, K., & Nakagawa, K. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.11.025 · Cited by 53
DNA Methyltransferases in Hematologic Malignancies
Li, K. K., Luo, L., Shen, Y., Xu, J., Zhu, C. H., & Chen, S. (2013) · Seminars in Hematology · doi:10.1053/j.seminhematol.2013.01.005 · Cited by 50
Recently approved therapies in acute myeloid leukemia: A complex treatment landscape
Talati, C., & Sweet, K. L. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.09.001 · Cited by 50
Precision Medicine in Oncology: In Vitro Drug Sensitivity and Resistance Test (DSRT) for Selection of Personalized Anticancer Therapy
Popova, A. A., & Levkin, P. A. (2020) · Advanced Therapeutics · doi:10.1002/adtp.201900100 · Cited by 50
Distinct Patterns of Clonal Evolution Drive Myelodysplastic Syndrome Progression to Secondary Acute Myeloid Leukemia
Guess, T. E., Potts, C. R., Bhat, P., Cartailler, J. A., Brooks, A., Holt, C., Yenamandra, A., Wheeler, F. C., Savona, M. R., Cartailler, J.-P., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0128 · Cited by 50
Concise Review: The Role of Hematopoietic Stem Cell Transplantation in the Treatment of Acute Myeloid Leukemia
Hamilton, B. K., & Copelan, E. A. (2012) · Stem Cells · doi:10.1002/stem.1140 · Cited by 51

Authors: Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., McMichael, J. F., Wallis, J. W., Lu, C., Shen, D., Harris, C. C., Dooling, D. J., Fulton, R. S., Fulton, L. L., Chen, K., Schmidt, H., Kalicki-Veizer, J., Magrini, V. J., Cook, L., McGrath, S. D., Vickery, T. L., Wendl, M. C., Heath, S., Watson, M. A., Link, D. C., Tomasson, M. H., Shannon, W. D., Payton, J. E., Kulkarni, S., Westervelt, P., Walter, M. J., Graubert, T. A., Mardis, E. R., Wilson, R. K., & DiPersio, J. F.
Affiliations: Washington University in St. Louis (US)
Corresponding author: Ley, Timothy J.
ORCID: Ding, Li
Ley, Timothy J.
Larson, David E.
Miller, Christopher A.
Koboldt, Daniel C.
Welch, John S.
Ritchey, Julie K.
McLellan, Michael D.
McMichael, Joshua F.
Lu, Charles
Shen, Dong
Fulton, Robert S.
Fulton, Lucinda L.
Chen, Ken
Magrini, Vincent J.
McGrath, Sean D.
Vickery, Tammi L.
Wendl, Michael C.
Heath, Sharon
Watson, Mark A.
Link, Daniel C.
Tomasson, Michael H.
Payton, Jacqueline E.
Kulkarni, Shashikant
Walter, Matthew J.
Graubert, Timothy A.
Mardis, Elaine R.
Wilson, Richard K.
DiPersio, John F.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2012-01
Volume: 481
Issue: 7382
Pages: 506-510
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature10738
PMC: PMC3267864
OpenAlex: W2093144236
Cited by: 1,993
References: 30
Citations by year: 2026: 55 · 2025: 50 · 2024: 61 · 2023: 74 · 2022: 116 · 2021: 138 · 2020: 134 · 2019: 151 · 2018: 155 · 2017: 160 · 2016: 197 · 2015: 192 · 2014: 210 · 2013: 182 · 2012: 118
FWCI: 149.48
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-sa
creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
Locations: Nature (publishedVersion, cc-by-nc-sa)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: Foundation for Barnes-Jewish Hospital (00335-0505-02)
National Human Genome Research Institute (U54HG003079, HG003079, NHGRI U54 HG003079)
National Cancer Institute (PO1CA101937, CA101937, P01CA101937)
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: acute myeloid leukemia, relapse, clonal evolution, somatic mutations, subclones, chemotherapy-induced DNA damage, transversions, recurrently mutated genes, WAC, SMC3, DIS3, DDX41, DAXX, clonality
MeSH terms: Antineoplastic Agents, Clone Cells, DNA Damage, DNA Mutational Analysis, Humans, Recurrence, Reproducibility of Results, Leukemia, Myeloid, Acute, Genome, Human, Mutagenesis, Genes, Neoplasm, High-Throughput Nucleotide Sequencing, Clonal Evolution

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks